Cogent Biosciences, Inc. (COGT)

Market Cap	5.30B +834.4%
Revenue (ttm)	n/a
Net Income	-354.30M
EPS	-2.51
Shares Out	170.91M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,795,094
Open	32.37
Previous Close	32.79
Day's Range	30.98 - 32.83
52-Week Range	5.49 - 43.73
Beta	0.35
Analysts	Strong Buy
Price Target	54.25 (+74.89%)
Earnings Date	May 5, 2026

About COGT

Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a rev...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 29, 2018
• Employees: 258
• Stock Exchange: NASDAQ
• Ticker Symbol: COGT
• Website: https://www.cogentbio.com

Analyst Summary

According to 13 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price target is $54.25, which is an increase of 74.89% from the latest price.

Price Target

$54.25

(74.89% upside)

Analyst Consensus: Strong Buy